In the study, the results of which were announced in the past days, and the effectiveness of giving only anti-hormonal therapy without chemotherapy to breast cancer patients who have spread to a small number of axillary lymphatics, that is, metastases, were investigated, it was shown that a good result could be obtained with only anti-hormonal treatments without chemotherapy in this group of patients. Anadolu Medical Center Medical Oncology Specialist Prof. Dr. Serdar Turhal said, “This study was based on the study conducted in the past years, which showed that by calculating the genetic risk in breast cancer patients who did not have spread to the axillary lymphatics, it is possible to obtain as good results as chemotherapy with only anti-hormone therapy without chemotherapy.”
Stating that in this new study, genetic risk calculations were made in 9383 female patients from 9 countries where the cancer spread to up to 3 axillary lymph nodes, Anadolu Medical Center Medical Oncology Specialist Prof. Dr. Serdar Turhal said, “2/3 of the patients were in menopause, and 1/3 of them were not menopausal yet. In this study, some of the patients who were calculated to have a low risk of genetic recurrence were given only hormone therapy, and some were given both chemotherapy and hormone therapy.
prof. Dr. Serdar Turhal continued his explanations as follows: “While chemotherapy had an additional contribution of 1.3 percent in women who did not enter menopause and had a low genetic recurrence score in the five-year follow-up, such an additional benefit of chemotherapy could not be shown in women who entered menopause. As a result, it has been shown that only anti-hormone therapy can be as effective as chemotherapy in patients with hormone receptor-positive menopause.”